Medical Device | February 13, 2023
A pharma industry veteran with over three decades of experience in domestic as well as international markets
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Subscribe To Our Newsletter & Stay Updated
